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enced a (biopsy proven) relapse. She went on to receive salvage
chemotherapy including carboplatin and cytoxan with stabiliza-
tion of disease, but without shrinkage in her tumor. Attempts to
collect peripheral blood stem cells upon recovery from chemo-
therapy using G-CSF at a dose of 24mcg/kg/day were unsuc-
cessful with only 1  105CD-34 positive stem cells per kg
collected over 3 days. In order to attempt to collect enough stem
cells for an autologous stem cell transplant, we obtained consent
from the AnorMED corporation and our institutional review
board for a PBSC collection using 4 days G-CSF at 10 mcg/kg
sc followed by 240 mcg/kg AMD3100 sc and subsequent aphere-
sis 10 hours later. We collected PBSCs for three days and
repeated this cycle a second time 30 days later, which allowed us
to collect 1.3  106CD34 positive stem cells per kg, more than
an order of magnitude greater than with G-CSF alone. There
were no untoward toxicities including no GI upset, paresthesias,
or injection site reactions, which have been previously reported
with adult patients. Pharmacokinetics were performed and were
similar to adults.
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IMPACT OF HIGH-RESOLUTION HLA MATCHING ON OUTCOMES OF
UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
Jang, J.H.1, Kang, S.Y.1, Park, J.S.1, Choi, J.H.1, Lim, H.Y.1,
Kim, H.C.1 Department of Hematology-Oncology, Ajou University
School of Medicine, Suwon, Korea.
Objective: We assessed the impact of high-resolution geno-
typic results of human leukocyte antigen (HLA) for all major
class I and II loci between donors and recipients in the outcome
of unrelated hematopoietic stem cell transplantation (HSCT).
Methods: Between 1999 and 2005, high-resolution genotyping
for HLA-A, -B, -C and -DRB1 was performed for 23 unrelated
HSCT. All the patients were typed as HLA identical by sero-
logic technique and then they were also typed HLA identical by
high resolution technique. Unrelated bone marrow transplan-
tation using DNA-based high resolution HLA compatibilities
were considered in the analyses of clinical outcomes such as
hematopoietic engraftment, acute GVHD, and survival. And
then, we compared with patients who received related HSCT
and also unrelated HSCT data from IBMTR. Results: Median
follow up duration was 9 months (1–51). Fifteen patients were
male and 8 were female. Median age was 22 years (range 6–52).
Median time from diagnosis to transplantation was 7 months
(range 4–63). Eight patients of acute myeloid leukemia (AML),
6 of chronic myeloid leukemia (CML, 2 of 6 were in blast crisis),
4 of acute lymphoid leukemia (ALL), 3 of severe aplastic anemia,
and each case of juvenile myelomonocytic leukemia and myelo-
dysplastic syndrome were enrolled. Median value of total nu-
cleated cell and CD34 positive cell count was 3.51 (1.06–
20.7)  108/kg and 4.88 (1.33–46.9)  106/kg, respectively. The
conditioning regimen and prophylaxis for graft versus host dis-
ease (GVHD) were not different from conventional HSCT
except one case of non-myeloablative transplantation. Median
value of granulocytic (absolute granulocyte count 	500/mm3)
and platelet (	20,000/mm3) engraftment were D  16, D  17,
respectively. Grade II acute GVHD developed in 4 patients (2
patients subsequently proceeded to chronic GVHD). Treatment
related mortality was 8.7% (2 out of 23 patients). Median value
of overall survival duration was 30 months. For AML patients,
3-year survival rate was 72.9%. Conclusions: Our survival data
for unrelated HSCT based on high resolution genotyped HLA
matching was inferior to related HSCT and superior to unre-
lated HSCT (of as expected). Although the sample size is small,
the survival data of AML patients (CR1) was superior to the
survivals of related HSCT as well as that of unrelated HSCT.
We suggest that transplantation using unrelated donors selected
by high-resolution genotype identity improves the transplanta-
tion outcomes.
IMMUNE RECONSTITUTION
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TRANSCRIPTIONAL MAPPING OF THE ANTI-VIRAL T CELL RESPONSE
SHOWS THAT IMPAIRED MEMORY DIFFERENTIATION CAUSES T CELL
DYSFUNCTION
Haining, W.N.1, Ebert, B.1,2, Subramanian, A.2, Golub, T.1,2,
Kaech, S.3, Wherry, E.J.4, Nadler, L.M.1 1.Dana-Farber Cancer In-
stutute, Boston, MA; 2. Broad Institute of Harvard and MIT, Cam-
bridge, MA; 3. Yale University, New Haven, CT; 4. Wistar Institute,
Phliadelphia, PA.
Human T cells responding to viral pathogens after HSCT can be
dysfunctional and ineffective even when present in adequate num-
bers. The basis for this qualitative, rather than quantitative, T cell
defect is not known.We hypothesized that impaired differentiation
of naive T cells into memory T cells causes a qualitative T cell
defect. We, therefore, studied CD8 T cell memory differentiation
in 2 murine models of LCMV infection: an acute infection in
which virus-speciﬁc T cells are fully functional and a chronic
infection model in which T cells are present in normal numbers
but are dysfunctional. In order to deﬁne how the differentiation
state of dysfunctional T cells in chronic infection differ from those
in acute infection, we generated gene expression proﬁles from
naive (day 0), effector (day 7 [d7]), and memory (day 30 [d30]) T
cells using oligonucleotide microarrays. In acute infection, T cell
states were so distinct that 100% of naive, effector, and memory
samples could be correctly classiﬁed, using a k-Nearest-Neighbor
prediction classiﬁer (kNN). Next, we hypothesized that the signa-
ture of normal memory T cells would contain gene-sets known to
be important in memory differentiation. We found that Stat-5
target genes were the most enriched gene-sets in memory cells
relative to naive cells of 	400 gene-sets tested (P  .004 by
permutation testing). This is consistent with the central role of
Stat-5 signaling in memory development. Lastly, we determined
where dysfunctional d30 T cells from chronic infection lie relative
to the “differentiation-space” of acute infection. None of the
chronic d30 T cell samples were classiﬁed as memory by kNN
prediction; all were misclassiﬁed as effectors. However, chronic
d30 T cells were not simply persistent effectors because chronic
d30 T cells showed marked differences in gene expression pattern
compared to d7 effectors. Thus, dysfunctional T cells in chronic
viral infection fail to complete normal memory differentiation and
are arrested in a distinct, effector-like phase. Our results show that
the disruption of memory differentiation causes qualitative T cell
dysfunction, and that this altered differentiation can be detected by
gene-expression proﬁling. We are now generating a global map of
antigen-speciﬁc T cell differentiation in humans. This gene-ex-
pression-based approach to evaluating immune reconstitution will
identify the mechanisms limiting the recovery of T cell memory
after HSCT.
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EXPRESSION OF INDIVIDUAL KILLER IMMUNOGLOBULIN-LIKE RECEP-
TOR (KIR) GENES MEASURED BY QUANTITATIVE REAL-TIME-PCR DI-
VIDES BLOOD NATURAL KILLER (NK) CELLS INTO THREE DEVELOP-
MENTALLY DISTINCT POPULATIONS
Cooley, S.A.1, Xiao, F.1, Pitt, M.1, McCullar, V.1, Bergemann, T.L.1,
McQueen, K.2, Parham, P.2, Miller, J.S.1 1. University of Minnesota,
Minneapolis, MN; 2. Stanford University, Palo Alto, CA.
Although hematopoietic cell transplant strategies that use KIR-
ligand mismatching to generate alloreactive NK cells have been
associated with improved clinical outcomes, the contributing ef-
fects of the fundamental processes regulating individual KIR ex-
pression are poorly understood. To study KIR emergence during
NK cell reconstitution, we created and validated a novel Quanti-
tative Real Time PCR (Q-PCR) expression typing assay to mea-
sure comparative KIR mRNA expression at the single gene level.
TaqMan primers and probes were designed for 13 KIR genes and
compared to genotyping. Analysis of 435 reactions run on mononu-
clear cells (5–15% NK cells) from 36 normal volunteers showed
excellent concordance between expression typing and genotyping:
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sensitivity (0.94), speciﬁcity (0.96), PPV (0.978) and Youden’s index
(0.9). The surface protein expression of KIR3DL1, measured by ﬂow
cytometry (DX9) correlated well with the relative expression by Q-
PCR (r  .418; P  .027). We then applied the Q-PCR assay to 3
discrete subpopulations of blood NK cells sorted using a cocktail of 3
antibodies (GL183, EB6 and DX9) that recognize 6 KIR genes
(CD56bright, CD56dimKIRAb, and CD56dimKIRAb-). Com-
pared to the combined CD56dimcell populations, CD56brightNK
cells (thought to be developmentally immature) had lower levels of
gene expression for all KIR except 2DL4. Interestingly, the
CD56dimKIRAb cells expressed higher amounts of the 7 KIR
genes not included in the sorting cocktail than did the
CD56dimKIR cells (median ratio of 5.05; P  .0001). The
CD56dimKIRAb cells had low gene expression for all KIR.
KIR2DL4, which is regulated differently than the other KIR, was the
most highly expressed gene in the CD56dimKIRAbcells. Addition-
ally, CD56dimKIRAb cells express a compensatory rise in NKG2A
(which precedes KIR expression duringNK development) when com-
pared to a CD56dimKIRAb population using ﬂow cytometry
(75.3 12.5% vs 32.0 6.6%; P .038). This demonstrates that the
mature, circulating population of CD56dim NK cells is comprised of
KIR-expressing and KIR-negative populations. Together, these re-
sults suggest that KIR expression may be a marker of maturation with
KIR acquisition under a common locus control mechanism. It also
identiﬁes a large population of mature NK cells lacking inhibitory
KIR that have the potential to become alloreactive if other inhibitory
interactions can be evaded.
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THE CLINICAL USE OF DONOR-DERIVED VIRUS-SPECIFIC CYTOTOXIC T
LYMPHOCYTES REACTIVE AGAINST CYTOMEGALOVIRUS (CMV), ADE-
NOVIRUS, AND EPSTEIN BARR VIRUS (EBV)
Bollard, C.M.1, Myers, G.D.1, Leen, A.1, Huls, H.1, Buza, E.1,
Chang, J.3, Leung, K.1, Carrum, G.1, Krance, R.A.1, Molldrem, J.2,
Brenner, M.K.1, Rooney, C.M.1, Heslop, H.E.1 1. Center for Cell and
Gene Therapy, Baylor College of Medicine, Houston, TX; 2. M. D.
Anderson Cancer Center, Houston, TX; 3. Department of Pathology,
The Methodist Hospital, Houston, TX.
CMV, Adenovirus (Ad), and EBV are major viral pathogens post
allogeneic SCT. Adoptive immunotherapy with donor-derived Cy-
totoxic T Lymphocytes (CTL) can prevent the clinical manifesta-
tions of EBV and CMV. We have extended these studies by
generating CTL from donor PBMC that can restore cellular im-
munity to CMV, EBV, and Ad simultaneously. Our protocol uti-
lizes stimulation with mononuclear cells transduced with a recom-
binant Ad type 5 vector pseudotyped with a type 35 ﬁber carrying
a transgene for the CMV antigen pp65, followed by 2 stimulations
with EBV-lymphoblastoid cell lines transduced with the same
vector. After 3 stimulations, 10 CTL cultures contained a mean of
83% (range 8.4–98.99%) CD8ve and a mean of 19.6% (range
2.2–91.6%) CD4ve cells. In Cr release /or IFNELISPOT
assays, all CTL lines showed speciﬁc activity against CMV and
EBV targets; 9/10 lines also showed speciﬁcity against Ad targets.
Further, using MHC-peptide multimers we have demonstrated the
simultaneous presence of CD8ve cells recognizing peptide
epitopes from CMV pp65 (range 2.32–21%) and Ad hexon (1.07–
8.08%) in the CTL cultures. We have treated 6 patients in this
phase I CMV prophylaxis study, 3 on DL1(1  107/m2) and 3 on
DL2(5 107/m2). Patients received one infusion of virus-speciﬁc
CTL from 54–120 days post SCT. We observed up to a 28-fold
increase in CMV pentamer ve CD8 T cells post CTL. At last
follow-up (12–40 wks post CTL infusion) all patients are CMV
and EBV neg. Two patients were transiently ve for CMV by
PCR 4–9 weeks post CTL but both were neg 7 days later without
anti-viral therapy, with a corresponding rise in CMV-speciﬁc CTL
detected in the peripheral blood. Two patients were culture ve
for Ad in stool/ blood pre-CTL therapy. One of these patients
was infected with Ad species from subgroups A, C, and D and the
other with group C alone. In both patients, we observed a 2-log
reduction of adenoviral load within 2–3 weeks post CTL infusion
at which time their symptoms (fever, loose stools) resolved. In
summary, we can efﬁciently generate multi-virus speciﬁc CTL.
Infusion of these cells included virus-speciﬁc CD8ve T cells in
the peripheral blood post CTL infusion. Further, reduction in Ad
load in stool/blood suggests efﬁcacy of Ad-speciﬁc CTL in vivo.
However, expansion of virus-speciﬁc CTL in vivo may require
presence of antigen. We will complete this prophylaxis study and
then proceed to using virus-speciﬁc CTL for the treatment of
CMV and Ad disease post SCT.
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ENHANCED IMMUNE RECONSTITUTION AND FUNCTION BY
CD4CD25 REGULATORY T CELLS FOLLOWING ALLOGENEIC HEMA-
TOPOIETIC CELL TRANSPLANTATION
Nguyen, V.H.1, Shashidar, S.1, Chang, D.S.1, Zeiser, R.1,
Brown, J.M.Y.1, Negrin, R.S.1 Stanford University School of Medicine,
Stanford, CA.
Regulatory T cells (Treg) reduce the incidence and severity of
acute graft-versus-host disease (GvHD) in murine models of ma-
jor-MHC mismatched hematopoietic cell transplantation (HCT).
It is unclear whether the effect of Treg on effector T cells is a
selective or nonselective process or if Treg regulate the process of
intrathymic and peripheral T cell maturation and selection follow-
ing HCT. The current study assessed the impact of Treg on the
quantitative and functional lymphoid reconstitution after HCT.
Treg from FVB/N (H2q) mice were co-transplanted into lethally
irradiated Balb/c (H2d) host along with FVB/N T cell depleted
bone marrow cells and CD4/CD8 cells, the latter to induce
GvHD. At days 14 and 40 post-transplantation, total lymphoid
reconstitution was delayed in the GvHD group and enhanced in
recipients transplanted with Treg (P  .0005 on day 14, P  .0001
on day 40). T cell reconstitution, particularly CD4 cells, was
enhanced in the Treg group at both time points and reached
statistical signiﬁcance on day 40 (P  .003). The number of donor
natural killer cells was particularly increased on day 14 in the Treg
recipients (P  .0003). B-cell reconstitution was enhanced at day
40 in recipient animals that received Treg (P  .006). T cell
repertoire assessed by V-beta TCR screening with FACS analysis
showed a polyclonal distribution. To determine if the improved
and diverse lymphoid reconstitution is associated with increased
immune function, mice were challenged with murine CMV intra-
peritoneally at day 14. Two weeks after infection, 66% of animals
that received Treg in addition to Tcon, and 11% of animals that
received Tcon alone were alive (P  .05). Uninfected mice in the
respective groups served as controls to separate the effect of CMV
infection and GvHD on survival. Compared to infected animals,
no deaths were observed in the respective uninfected groups at this
time point (Tcon alone, P  .0004; Treg  Tcon, P  .21). In
both infected and control uninfected animals, Treg treated animals
had no evidence of signiﬁcant clinical GvHD compared to animals
that received Tcon alone. Decreased viral load and increased
CMV-speciﬁc T cell response in the Treg group conﬁrmed sur-
vival outcomes (P  .05). These ﬁndings indicate that Treg en-
hance both the quantitative and functional recovery of the lym-
phoid cell populations while providing protection against GvHD.
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ACCELERATED IMMUNE RECOVERY FOLLOWING LLME TREATED DO-
NOR LYMPHOCYTE INFUSION
Filicko, J.1, Grosso, D.1, Flomenberg, P.R.1, Brunner, J.1, Dessain, S.1,
Drobyski, W.2, Ferber, A.1, Friedman, T.3, Kahkniashvili, I.1,
Keever-Taylor, C.2, Mookerjee, B.1, Wagner, J.L.1, Korngold, R.3,
Flomenberg, N.1 1. Thomas Jefferson University, Philadelphia, PA; 2.
Medical College of Wisconsin, Milwaukee, WI; 3. Hackensack University
Cancer Center, Hackensack, NJ.
Delayed immune reconstitution is a major cause of morbidity and
mortality after T cell depleted allogeneic progenitor cell transplant
(PCT). To accelerate immune reconstitution without GVHD, we
have administered escalating doses of L-leucyl-L-leucine methyl
ester (LLME) treated lymphocytes (DLI) to 18 patients post
CD34 cell-enriched PCT in an ongoing phase I trial. LLME’s
cellular toxicity occurs after polymerization by dipeptidyl pepti-
dase, leading to selective depletion of cells with cytotoxic effector
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